These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 28967548)

  • 1. Asthma Cost-Effectiveness Analyses: Are We Using the Recommended Outcomes in Estimating Value?
    Kim CH; Dilokthornsakul P; Campbell JD; van Boven JFM
    J Allergy Clin Immunol Pract; 2018; 6(2):619-632. PubMed ID: 28967548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporating adherence in cost-effectiveness analyses of asthma: a systematic review.
    Chongmelaxme B; Chaiyakunapruk N; Dilokthornsakul P
    J Med Econ; 2019 Jun; 22(6):554-566. PubMed ID: 30663455
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations.
    McQueen RB; Sheehan DN; Whittington MD; van Boven JFM; Campbell JD
    Pharmacoeconomics; 2018 Aug; 36(8):957-971. PubMed ID: 29736895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness analysis of first-line controller therapies for persistent asthma.
    Shih YC; Mauskopf J; Borker R
    Pharmacoeconomics; 2007; 25(7):577-90. PubMed ID: 17610338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of asthma therapy: a comprehensive review.
    Domínguez-Ortega J; Phillips-Anglés E; Barranco P; Quirce S
    J Asthma; 2015; 52(6):529-37. PubMed ID: 25539023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter?
    Dilokthornsakul P; Chaiyakunapruk N; Campbell JD
    J Asthma; 2017 Jan; 54(1):17-23. PubMed ID: 27284904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Medication adherence in asthma therapy--a structured review].
    Fischer J; Wimmer A; Mahlich J
    Pneumologie; 2013 Jul; 67(7):406-14. PubMed ID: 23797492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions.
    Ehteshami-Afshar S; Zafari Z; Hamidi N; FitzGerald JM; Lynd L; Sadatsafavi M
    Value Health; 2019 Sep; 22(9):1070-1082. PubMed ID: 31511184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review.
    Rodriguez-Martinez CE; Sossa-Briceño MP; Castro-Rodriguez JA
    Pharmacoeconomics; 2018 Oct; 36(10):1165-1200. PubMed ID: 29869050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health economics of asthma: assessing the value of asthma interventions.
    Campbell JD; Spackman DE; Sullivan SD
    Allergy; 2008 Dec; 63(12):1581-92. PubMed ID: 19032230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
    Dal Negro RW; Tognella S; Pradelli L
    J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis.
    Faria R; McKenna C; Palmer S
    Value Health; 2014 Dec; 17(8):772-82. PubMed ID: 25498772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cluster randomised control trial to evaluate the effectiveness and cost-effectiveness of the Italian medicines use review (I-MUR) for asthma patients.
    Manfrin A; Tinelli M; Thomas T; Krska J
    BMC Health Serv Res; 2017 Apr; 17(1):300. PubMed ID: 28438152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost effectiveness of treatment with salmeterol/fluticasone compared to montelukast for the control of persistent asthma in children].
    Rely K; McQuire SE; Alexandre PK; Escudero GS
    Value Health; 2011; 14(5 Suppl 1):S43-7. PubMed ID: 21839898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of risk factors and health outcomes among persons with asthma.
    Smith K; Warholak T; Armstrong E; Leib M; Rehfeld R; Malone D
    J Asthma; 2009 Apr; 46(3):234-7. PubMed ID: 19373629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
    Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective.
    Levy AN; García A Ruiz AJ; García-Agua Soler N; Sanjuan MV
    J Asthma; 2015 Mar; 52(2):205-10. PubMed ID: 24995661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asthma outcomes: healthcare utilization and costs.
    Akinbami LJ; Sullivan SD; Campbell JD; Grundmeier RW; Hartert TV; Lee TA; Smith RA
    J Allergy Clin Immunol; 2012 Mar; 129(3 Suppl):S49-64. PubMed ID: 22386509
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.